祝银萍,张兴平.复方丹参片联合辛伐他汀治疗冠心病的临床研究[J].现代药物与临床,2019,34(5):1323-1327
复方丹参片联合辛伐他汀治疗冠心病的临床研究
Clinical study on Compound Danshen Tablets combined with simvastatin in treatment of coronary heart disease
投稿时间:2019-02-25  
DOI:10.7501/j.issn.1674-5515.2019.05.012
中文关键词:  复方丹参片  辛伐他汀片  冠心病  心功能  炎性因子  血脂
英文关键词:Compound Danshen Tablets  Simvastatin Tablets  coronary heart disease  cardiac function  inflammatory factor  blood lipid
基金项目:
作者单位E-mail
祝银萍 西南医科大学附属医院, 四川泸州 646000  
张兴平 西南医科大学附属医院, 四川泸州 646000
重庆市人民医院老年科, 重庆 400010 
13628164819@163.com 
摘要点击次数: 113
全文下载次数: 120
中文摘要:
      目的 研究复方丹参片联合辛伐他汀片治疗冠心病的临床疗效。方法 选取2016年7月—2018年7月重庆市人民医院收治的100例冠心病患者作为研究对象,采用随机数字表法将患者分为对照组(50例)和治疗组(50例)。对照组患者口服辛伐他汀片,10 mg/次,晚间顿服,1次/d;治疗组在对照组治疗基础上口服复方丹参片,3片/次,3次/d。两组患者均治疗8周。观察两组患者的临床疗效和心电图疗效,比较两组治疗前后的心功能指标、血清炎性因子水平、心肌酶指标和血脂水平。结果 治疗后,对照组临床疗效和心电图疗效分别为86.00%、84.00%,均分别显著低于治疗组的96.00%、94.00%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者左室舒张末内径(LVEED)、左房内径(LADD)和左室收缩末内径(LVESD)均显著降低,左心射血分数(LVEF)、心输出量(CO)、心脏指数(CI)和每搏心输出量(SV)水平均显著升高(P<0.05);且治疗后治疗组的心功能指标显著优于对照组(P<0.05)。治疗后,两组C-反应蛋白(CRP)、白细胞介素-6(IL-6)和血清肿瘤坏死因子-α(TNF-α)水平均显著降低(P<0.05);且治疗后治疗组的血清炎性因子水平显著低于对照组(P<0.05)。治疗后,两组患者肌酸激酶MB型同工酶(CKMB)、肌酸激酶(CK)水平显著降低(P<0.05);且治疗后治疗组心肌酶水平显著低于对照组(P<0.05)。治疗后,两组患者高密度脂蛋白胆固醇(HDL-C)水平显著升高,低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)和总胆固醇(TC)水平均显著降低(P<0.05);且治疗后治疗组的血脂水平显著优于对照组(P<0.05)。结论 复方丹参片联合辛伐他汀片治疗冠心病具有较好的临床疗效,能够改善心功能,降低患者血清炎性因子和血脂水平,具有一定的临床推广使用价值。
英文摘要:
      Objective To study the clinical efficacy of Compound Danshen Tablets combined with Simvastatin Tablets in treatment of coronary heart disease. Methods Patients (100 cases) with coronary heart disease in Chongqing General Hospital from July 2016 to July 2018 were divided into control (50 cases) and treatment (50 cases) groups. Patients in the control group were po administered with Simvastatin Tablets in the evening, 10 mg/time, once daily. Patients in the treatment group were po administered with Compound Danshen Tablets on the basis of control group, 3 tablets/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy and ECG efficacy were evaluated, and the cardiac function indexes, serum inflammatory factors level, myocardial enzyme indexes, and the blood lipid level before and after treatment in two groups were compared. Results After treatment, the clinical efficacy and ECG efficacy in the control group were 86.00% and 84.00%, which were significantly lower than 96.00% and 94.00% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the LVEED, LADD, and LVESD levels in two groups were significantly decreased, but the LVEF, CO, CI, and SV levels were significantly increased (P < 0.05). And these cardiac function indexes in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the levels of CRP, IL-6, and TNF-α in two groups were significantly decreased (P< 0.05). And the levels of serum inflammatory factors in the treatment group after treatment were significantly lower than those in the control group (P< 0.05). After treatment, the levels of CKMB and CK in two groups were significantly decreased (P< 0.05). And the levels of myocardial enzyme indexes in the treatment group after treatment were significantly lower than those in the control group (P< 0.05). After treatment, the HDL-C levels in two groups were significantly increased, but the LDL-C, TG, and TC levels were significantly decreased (P < 0.05). And blood lipid levels in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Compound Danshen Tablets combined with Simvastatin Tablets has a good clinical effect in treatment of coronary heart disease, can improve the cardiac function, reduce serum inflammatory factors and the blood lipid levels, which has a certain clinical application value.
HTML  查看全文  查看/发表评论  下载PDF阅读器
关闭
您是第 6064367 位访客
版权所有 天津中草药杂志社(天津市南开区鞍山西道308号 300193)
联系电话:022-23006823 传真:022-23006823 E_mail:dc@tiprpress.com
津备案:津ICP备13000267号 互联网药品信息服务资格证书编号:(津)-非经营性-2015-0031